Ch Javed Iqbal, Najam Iqbal Chaudhary, Nabeel Shahab.
Comparison of IOP alterations following 2mg & 4mg Intravitreal Trimcinolone Acetonide (IVTA) in Clinically Significant Macular Edema (CSME).
Ophthalmol Update Jan ;13(3):196-9.

Introduction: Triamcinolone acetonide is a synthetic glucocorticoid which is used for the treatment of clinically significant Macular edema. The rise in the intraocular pressure is a main side effect of its use. Ophthalmologists have to out weight the risk of side effects for its use. Our aim in this study is to compare the intraocular pressure (IOP) alterations after giving 2mg and 4mg intravitreal triamcinolone acetonide in patients with clinically significant macular edema (CSME). Material & Methods: This randomized controlled trial was conducted at Institute of Ophthalmology, Mayo Hospital Lahore. Sample size of 80 cases was included through non-probability purposive sampling technique. All the patients in the study gave informed consent and their demographics were recorded. Pre-injection IOP and general evaluation of patients were done. The cases were randomly divided in two groups. In one group, 2mg intravitreal triamcinolone acetonide was given while in group two, 4mg intravitreal triamcinolone acetonide was given. Patients were followed for 3 months to measure the mean increase in IOP level in both groups. Results: Patient mean age was 48.68±5.60 years. In this study, there were 45% males while 55% patients were females. In right eye, at baseline the mean value of IOP was 13.48±3.48mmHg. After 3 months the mean value of IOP was 11.69±2.59mmHg with 2mg whereas 14.82±3.88mmHg with 4mg. Conclusion: It was concluded that 2mg dose of intravitreal triamcinolone acetonide is more beneficial in terms of less increase in IOP as compared to 4mg intravitreal triamcinolone acetonide (IVTA) injection to decrease CSME.

PakMediNet -Pakistan's largest Database of Pakistani Medical Journals - http://www.pakmedinet.com